XOMA Corporation is a biotechnology company with a diverse portfolio of innovative therapeutic antibodies. The Company’s innovative product candidates are the result of its expertise in developing ground-breaking monoclonal antibodies, which have created new opportunities to potentially treat a wide range of endocrine diseases.
XOMA's scientific research produced a portfolio of five endocrine assets, each of which has the opportunity to address multiple indications. Two of the assets were developed through the XOMA Metabolic or XMet platform, which consists of separate classes of Selective Insulin Receptor Modulators (SIRMs) that could have a major impact on the treatment of metabolic disorders.
XOMA is located in Berkeley, California.
Oct 14, 2016
XOMA Announces Reverse Stock Split
Sep 15, 2016 at 4:30 PM ET
XOMA 358 Clinical Update Webcast
Aug 17, 2016 at 3:40 PM ET
Wedbush Pacgrow Healthcare Conference